1.1Oxygen at the X position
The oxygen forms two single bonds to its ring neighbors. The five-membered ring constrains the directions of the attached groups, and an oxygen lone pair provides a hydrogen-bond acceptor at X.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The oxygen forms two single bonds to its ring neighbors. The five-membered ring constrains the directions of the attached groups, and an oxygen lone pair provides a hydrogen-bond acceptor at X.
The nitrile carbon bonds directly to the ring carbon at X. The linear C≡N group projects a hydrogen-bond acceptor along the substituent axis and withdraws electron density from the ring.
Sulfur forms two single bonds to the neighboring carbons in the ring. Its longer carbon–sulfur bonds change the local ring geometry, and its polarizable electron density supports dispersion contacts in a binding pocket.
The scaffold bonds directly to carbon 5 of the tetrazole. Deprotonation distributes negative charge over the ring nitrogens, providing an anionic site for electrostatic contact with a basic residue.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Seed fibroblasts carrying a TEAD-responsive luminescent reporter onto hydrogels of different stiffness coated with the same adhesion protein. Apply the inhibitor and its vehicle in separate wells at each stiffness. Divide reporter luminescence by viable cell count and compare inhibitor-treated wells with vehicle-treated wells at each stiffness to measure the TEAD-dependent contribution to the response.
Replace the oxygen atom in an ether-linked member with sulfur at linker position L. Retain the attachment atoms on both sides of the linker so the thioether joins the same fragments as the ether. Prepare the thioether by reacting a thiol on one fragment with an alkyl halide on the other fragment. Compare the two compounds in a TEAD binding assay and measure aqueous solubility separately.
Run a cell-based TEAD reporter assay in 384-well plates at 40 microliters per well. Dose the inhibitor in duplicate at eight concentrations in a threefold dilution series starting at 10 micromolar, with 0.1 percent dimethyl sulfoxide in all test and vehicle wells. After 24 hours, measure reporter luminescence and use a parallel viability plate to identify concentrations that reduce viable cell count.
Immobilize a purified TEAD domain on one flow cell of a surface plasmon resonance sensor and use a second flow cell as a reference. Inject a concentration series of the inhibitor over both flow cells in solvent-matched running buffer. Subtract the reference and buffer responses, then fit the corrected equilibrium responses to estimate the dissociation constant.
Place cells carrying a TEAD-responsive reporter in a microfluidic chamber supplied by independently selectable vehicle and inhibitor reservoirs. Perfuse vehicle to establish the baseline, switch to inhibitor-containing medium for a defined exposure, then switch back to vehicle at the same flow rate. Image the reporter at fixed intervals and collect outlet samples for liquid chromatography with mass spectrometry to relate reporter recovery to compound clearance from the chamber.
RX is a phenyl group that bonds to X through carbon 1. A methyl group at carbon 4 extends the hydrophobic surface along the phenyl ring's attachment axis.
Y is a ring carbon bearing a directly attached cyano group. The terminal nitrogen provides a hydrogen-bond acceptor at the end of the linear C≡N unit.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
R1 is selected from the group consisting of —Y2-alkyl-N(R4)R5, hydrogen, deuterium, halogen, alkyl, alkenyl, alkynyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, aminoalkyl, acyl, carboxylalkyl, carbonyl, carboxyl, cyano, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, oxo, alkylthio, thiolalkyl, mercaptyl, thiol, sulfonate, sulfonamido, alkylsulfonyl, amino, amido, alkylamino, dialkylamino, carbamate, nitro, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyloxy,A · US 2014/0066424 A1 · ¶
cycloalkylcarbonyl, arylcarbonyl, heterocycloalkylcarbonyl, heteroarylcarbonyl, cycloalkylalkyl, arylalkyl, heterocycloalkylalkyl, heterocycloalkylcarbonylalkyl, and heteroarylalkyl, any of which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkenyl, alkynyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, amidoalkyl, acyl, carbonyl, carboxyl, carboxylalkyl, alkylcarbonyl, heteroalkylA · US 2014/0066424 A1 · ¶
Rx is hydrogen, —NO2, —CN, or —S(═O)2Ra; each R4 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R4a; each R4a is independently oxo, deuterium, halogen, —CN, —ORb, —NRcRdB · US 2022/0017566 A1 · ¶
R3 is selected from the group consisting of hydrogen, deuterium, halogen, alkyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, acyl, carbonyl, carboxyl, cyano, cyanoalkyl, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, alkoxyalkoxy, hydroxyalkoxy, oxo, alkylthio, mercaptyl, thiol, haloalkylthio, perhaloalkylthio, cyanoalkylthio, haloalkylsulfonyl, alkylsulfonyl, alkoxyalkylsulfonyl, cyanoalkylsulfonyl, sulfonate, sulfonamido, amino, amido, alkylamiA · US 2014/0066424 A1 · ¶
E is selected from the group consisting of aryl and heteroaryl; G is selected from the group consisting of saturated 3- to 7-membered cycloalkyl and saturated 3- to 7-membered heterocycloalkyl;A · US 2014/0066424 A1 · ¶
wherein: Ring A is a cycloalkyl or a heterocycloalkyl;B · US 2022/0017566 A1 · ¶
R1 is hydrogen, deuterium, halogen, —CN, —ORb, —NRcRd, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, or C1-C6 heteroalkyl; each R2 is independently deuterium, halogen, —CN, —ORb, —NRcRd, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cyB · US 2022/0017566 A1 · ¶
heterocycloalkylcarbonylalkyl, and heterocycloalkylcarbonyl, any of which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkenyl, amidoalkyl, acyl, carboxylalkyl, hydroxyalkylcarbonyl, alkynylcarbonyl, heteroalkyl, hydroxyalkyl, alkoxyalkyl, carboxyl, cyano, hydroxy, alkoxy, oxo, sulfonamido, alkylsulfonyl, amino, amido, carbamate, dialkylamino, dialkylaminoalkyl, trisubstituted siloxy, cyA · US 2014/0066424 A1 · ¶
Rx is hydrogen, —NO2, —CN, or —S(═O)2Ra; each R4 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three lea; each R4a is independently oxo, deuterium, halogen, —CN, —ORb, —NRcRdB · US 2022/0017566 A1 · ¶
Y1 is alkyl, which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, and halogen; and Y2 is selected from the group consisting of a bond, carbonyl, alkylcarbonyl, carboxyl, oxy, thio, sulfinyl, sulfonyl, sulfonamido, amino, amido, alkylamino, and carbamate, any of which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, haA · US 2014/0066424 A1 · ¶
wherein: Ring B is a cycloalkyl or a heterocycloalkyl; each R14 is independently deuterium, halogen, —CN, —ORb, —NRcRd, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, or heterocycloalkyl; m is 0-6;B · US 2022/0017566 A1 · ¶
An empty cell means only that no passage was reproduced there.
Methods to inhibit HIF pathway activity through the degradation of the HIFα protein subunits in a human or animal subject are also provided for the treatment of diseases mediated by HIF pathway activity.A · US 2014/0066424 A1 · ¶ 2
HIF mediated survival of cells in hypoxia is a major contributor to resistance to therapies, lack of durable response and the foundation of residual disease.A · US 2014/0066424 A1 · ¶ 8
The anti-inflammatory and anti-proliferative activity of the naturally occurring triterpenoid, oleanolic acid, has been improved by chemical modifications.B · US 2022/0017566 A1 · ¶ 3
Compounds derived from oleanolic acid have been shown to affect the function of multiple protein targets and thereby modulate the activity of several important cellular signaling pathways related to oxidative stress, cell cycle control, and inflammation.B · US 2022/0017566 A1 · ¶ 4
patent.fyi, US 2026/0356806 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356806/, SHA-256 4773ee7a761fce98e2286634e4a6b601d2d2f49366c0f84a94ee748ebf0bffa0